Olanzapine N-Oxide
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 581003

CAS#: 174794-02-6

Description: Olanzapine N-oxide is a metabolite of Olanzapine. Olanzapine (originally branded Zyprexa) is an antipsychotic medication used to treat schizophrenia and bipolar disorder.


Price and Availability

Size
Price

2mg
USD 450
Size
Price

Size
Price

Olanzapine N-Oxide, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 581003
Name: Olanzapine N-Oxide
CAS#: 174794-02-6
Chemical Formula: C17H20N4OS
Exact Mass: 328.1358
Molecular Weight: 328.43
Elemental Analysis: C, 62.17; H, 6.14; N, 17.06; O, 4.87; S, 9.76


Synonym: Olanzapine N-oxide

IUPAC/Chemical Name: 1-Methyl-4-(2-methyl-10H-benzo[b]thieno[2,3-e][1,4]diazepin-4-yl)piperazine 1-oxide

InChi Key: LJVNYCDXBXGQIK-UHFFFAOYSA-N

InChi Code: InChI=1S/C17H20N4OS/c1-12-11-13-16(20-7-9-21(2,22)10-8-20)18-14-5-3-4-6-15(14)19-17(13)23-12/h3-6,11,19H,7-10H2,1-2H3

SMILES Code: CC(S1)=CC2=C1NC3=CC=CC=C3N=C2N4CC[N+](C)([O-])CC4


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
293490


References

1: Okubo M, Narita M, Murayama N, Akimoto Y, Goto A, Yamazaki H. Individual differences in in vitro and in vivo metabolic clearances of the antipsychotic drug olanzapine from non-smoking and smoking Japanese subjects genotyped for cytochrome P4502D6 and flavincontaining monooxygenase 3. Hum Psychopharmacol. 2016 Mar;31(2):83-92. doi: 10.1002/hup.2515. Epub 2016 Feb 8. PubMed PMID: 26856397.

2: Johnson JT, Everly AG, Kpakima FE, Detke HC. Postmortem redistribution of olanzapine following intramuscular administration of olanzapine pamoate in dogs. Forensic Sci Int. 2015 Dec;257:353-8. doi: 10.1016/j.forsciint.2015.09.022. Epub 2015 Oct 22. PubMed PMID: 26517823.

3: Korprasertthaworn P, Polasek TM, Sorich MJ, McLachlan AJ, Miners JO, Tucker GT, Rowland A. In Vitro Characterization of the Human Liver Microsomal Kinetics and Reaction Phenotyping of Olanzapine Metabolism. Drug Metab Dispos. 2015 Nov;43(11):1806-14. doi: 10.1124/dmd.115.064790. Epub 2015 Sep 1. PubMed PMID: 26329789.

4: Söderberg MM, Dahl ML. Pharmacogenetics of olanzapine metabolism. Pharmacogenomics. 2013 Aug;14(11):1319-36. doi: 10.2217/pgs.13.120. Review. PubMed PMID: 23930678.

5: Söderberg MM, Haslemo T, Molden E, Dahl ML. Influence of FMO1 and 3 polymorphisms on serum olanzapine and its N-oxide metabolite in psychiatric patients. Pharmacogenomics J. 2013 Dec;13(6):544-50. doi: 10.1038/tpj.2012.47. Epub 2012 Nov 13. PubMed PMID: 23147717.

6: Haslemo T, Olsen K, Lunde H, Molden E. Valproic Acid significantly lowers serum concentrations of olanzapine-an interaction effect comparable with smoking. Ther Drug Monit. 2012 Oct;34(5):512-7. doi: 10.1097/FTD.0b013e3182693d2a. PubMed PMID: 22972535.

7: Habicht SC, Duan P, Vinueza NR, Fu M, Kenttämaa HI. Liquid chromatography/tandem mass spectrometry utilizing ion-molecule reactions and collision-activated dissociation for the identification of N-oxide drug metabolites. J Pharm Biomed Anal. 2010 Mar 11;51(4):805-11. doi: 10.1016/j.jpba.2009.09.047. Epub 2009 Oct 7. PubMed PMID: 19897332.

8: Nagashima S, Shimizu M, Yano H, Murayama N, Kumai T, Kobayashi S, Guengerich FP, Yamazaki H. Inter-individual variation in flavin-containing monooxygenase 3 in livers from Japanese: correlation with hepatic transcription factors. Drug Metab Pharmacokinet. 2009;24(3):218-25. PubMed PMID: 19571433; PubMed Central PMCID: PMC4755719.

9: Cashman JR, Zhang J, Nelson MR, Braun A. Analysis of flavin-containing monooxygenase 3 genotype data in populations administered the anti-schizophrenia agent olanzapine. Drug Metab Lett. 2008 Apr;2(2):100-14. PubMed PMID: 19356079.

10: Duan P, Fu M, Gillespie TA, Winger BE, Kenttämaa HI. Identification of aliphatic and aromatic tertiary N-oxide functionalities in protonated analytes via ion/molecule and dissociation reactions in an FT-ICR mass spectrometer. J Org Chem. 2009 Feb 6;74(3):1114-23. doi: 10.1021/jo802001e. PubMed PMID: 19133762.

11: Williams JB, Mallorga PJ, Conn PJ, Pettibone DJ, Sur C. Effects of typical and atypical antipsychotics on human glycine transporters. Schizophr Res. 2004 Nov 1;71(1):103-12. PubMed PMID: 15374578.

12: Kratzsch C, Peters FT, Kraemer T, Weber AA, Maurer HH. Screening, library-assisted identification and validated quantification of fifteen neuroleptics and three of their metabolites in plasma by liquid chromatography/mass spectrometry with atmospheric pressure chemical ionization. J Mass Spectrom. 2003 Mar;38(3):283-95. PubMed PMID: 12644990.

13: Callaghan JT, Bergstrom RF, Ptak LR, Beasley CM. Olanzapine. Pharmacokinetic and pharmacodynamic profile. Clin Pharmacokinet. 1999 Sep;37(3):177-93. Review. PubMed PMID: 10511917.

14: Murphy AT, Lake BG, Bernstein JR, Franklin RB, Gillespie TA. Characterization of olanzapine (LY170053) in human liver slices by liquid chromatography/tandem mass spectrometry. J Mass Spectrom. 1998 Dec;33(12):1237-45. PubMed PMID: 9875525.

15: Mattiuz E, Franklin R, Gillespie T, Murphy A, Bernstein J, Chiu A, Hotten T, Kassahun K. Disposition and metabolism of olanzapine in mice, dogs, and rhesus monkeys. Drug Metab Dispos. 1997 May;25(5):573-83. PubMed PMID: 9152596.

16: Kassahun K, Mattiuz E, Nyhart E Jr, Obermeyer B, Gillespie T, Murphy A, Goodwin RM, Tupper D, Callaghan JT, Lemberger L. Disposition and biotransformation of the antipsychotic agent olanzapine in humans. Drug Metab Dispos. 1997 Jan;25(1):81-93. PubMed PMID: 9010634.

17: Schlicker E, Marr I. The moderate affinity of clozapine at H3 receptors is not shared by its two major metabolites and by structurally related and unrelated atypical neuroleptics. Naunyn Schmiedebergs Arch Pharmacol. 1996 Feb;353(3):290-4. PubMed PMID: 8692283.

18: Ring BJ, Catlow J, Lindsay TJ, Gillespie T, Roskos LK, Cerimele BJ, Swanson SP, Hamman MA, Wrighton SA. Identification of the human cytochromes P450 responsible for the in vitro formation of the major oxidative metabolites of the antipsychotic agent olanzapine. J Pharmacol Exp Ther. 1996 Feb;276(2):658-66. PubMed PMID: 8632334.